公开(公告)号：US20240360209A1

公开(公告)日：2024-10-31

申请号：US18623647

申请日：2024-04-01

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07K16/24 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61P25/00 ,  A61P25/02 ,  A61P29/00 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20220144932A1

公开(公告)日：2022-05-12

申请号：US17290154

申请日：2019-12-31

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Dong Sik KIM ,  Jae-Keun LEE ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN

IPC: C07K16/24

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In some embodiments, antibodies are de-immunized to reduce immunogenicity in a human subject. In certain embodiments, antibodies have undergone affinity maturation. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g, inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

公开(公告)号：US20210054062A1

公开(公告)日：2021-02-25

申请号：US17054469

申请日：2019-05-10

Applicant: Neuracle Science Co., Ltd. ,  Seoul National University R&DB Foundation

Inventor： Bongcheol KIM ,  Wonkyum KIM ,  Jeongwon YOON ,  Junho CHUNG ,  Junyeong JIN ,  Eunhwoi YOU

IPC: C07K16/24 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00 ,  A61P29/00 ,  A61P25/02

Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Ina specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.